DSGN — Design Therapeutics Share News
0.000.00%
Last trade - 00:00- $656.48m
- $449.09m
U.S. STOCKS ON THE MOVE-Getty Images, Tiziana, LL Flooring
U.S. STOCKS ON THE MOVE-SCYNEXIS, Paysafe, Big banks
Design Therapeutics slumps on setback to nerve disorder drug trial
Design Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Design Therapeutics Reports Initial Results From Phase 1 Multiple-Ascending Dose Study Of Dt-216 For The Treatment Of Friedrich Ataxia
Brief: Design Therapeutics Q2 Basic EPS USD -0.36
Design Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview
Design Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Design Therapeutics posts Q1 basic EPS USD -0.35
Brief: Design Therapeutics Provides Pipeline Updates And Reports First Quarter 2023 Financial Results
Design Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Design Therapeutics: On-Track To Submit Investigational New Drug Application For DT-168
Brief: Design Therapeutics Highlights Pipeline Progress And Reports Q4 And Full Year 2022 Financial Results
Design Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Design Therapeutics Q4 operating loss USD 19.392 million
Design Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Regenxbio, Hello Group, copper miners
U.S. STOCKS ON THE MOVE-Express, Hershey, Entrada Therapeutics
U.S. STOCKS ON THE MOVE-Rent the Runway, Pharvaris, U.S. energy firms